Search Results - "Frost, Nicolaj"

Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC by Reck, Martin, Lee, Ki Hyeong, Frost, Nicolaj, Breder, Valeriy Vladimirovich, Kowalski, Dariusz, Levchenko, Evgeny, Reguart, Noemi, Martinez-Marti, Alex, Houghton, Baerin, Paoli, Jean-Baptiste, Safina, Sufiia, Komiya, Takefumi, Sanford, Amy, Liu, Hong, Song, Andrew J., Keller, Steven M., Jabbour, Salma K.

“…8508 Background: Primary analysis (database cutoff, Oct 28, 2020) of the global KEYNOTE-799 study (NCT03631784) in patients (pts) with unresectable, locally…”
Get full text

Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799 by Jabbour, Salma K., Lee, Ki Hyeong, Frost, Nicolaj, Kowalski, Dariusz, Breder, Valeriy Vladimirovich, Pollock, Theodore, Reguart, Noemi, Houghton, Baerin, Quantin, Xavier, Keller, Steven M., Liu, Hong, Piperdi, Bilal, Reck, Martin

“…Abstract only 9008 Background: KEYNOTE-799 (NCT03631784) evaluates pembro plus concurrent chemoradiation therapy (CCRT) in pts with unresectable, locally…”
Get full text

KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC by Jabbour, Salma K., Lee, Ki Hyeong, Frost, Nicolaj, Breder, Valeriy Vladimirovich, Kowalski, Dariusz M., Alawin, Issam Abdelkarim, Levchenko, Evgeny, Reguart, Noemi, Martinez-Marti, Alex, Houghton, Baerin, Paoli, Jean-Baptiste, Safina, Sufia, Park, Keunchil, Komiya, Takefumi, Sanford, Amy, Boolell, Vishal, Liu, Hong, Samkari, Ayman, Keller, Steven M., Reck, Martin

“…Abstract only 8512 Background: KEYNOTE-799 (NCT03631784) is an ongoing study of the anti‒PD-1 antibody pembrolizumab (pembro) plus concurrent chemoradiation…”
Get full text